

SUPPORTING INFORMATION

Structural Studies of (*rac*)-BIPHEN Organomagnesiates and Intermediates in the Halogen-metal Exchange of 2-Bromopyridine

Javier Francos, Philippe C. Gros,^{*} Alan R. Kennedy, and Charles T. O'Hara^{*}

General Methods

All reactions were performed under a protective argon atmosphere using standard Schlenk techniques. Hexane and THF were obtained from Aldrich and freshly distilled from sodium/benzophenone prior to use. $(\text{CH}_2\text{SiMe}_3)_2\text{Mg}$ and $(\text{CH}_2\text{CMe}_3)_2\text{Mg}$ were prepared from the Grignard reagent $(\text{CH}_2\text{SiMe}_3)\text{MgCl}$ and $(\text{CH}_2\text{CMe}_3)\text{MgCl}$ by manipulation of the Schlenk equilibrium via the dioxane precipitation method. The resultant off-white solid was purified via sublimation at 175 °C (10^{-2} Torr) to furnish pure $(\text{CH}_2\text{SiMe}_3)_2\text{Mg}$ and $(\text{CH}_2\text{CMe}_3)_2\text{Mg}$. Other chemicals were obtained from Aldrich or Strem Chemicals and were used as supplied. ^1H and ^{13}C NMR spectra were recorded on a Bruker DPX 400 MHz spectrometer. All ^{13}C NMR spectra were proton decoupled. Elemental analyses were attempted using a Perkin-Elmer 2400 elemental analyzer; however, due to the extreme air sensitivity of the compounds satisfactory analyses could not be obtained.

Synthesis of [(*rac*)-BIPHEN] $_2\text{Li}_4(\text{THF})_4 \cdot (\text{THF})$ (1). (*rac*)-BIPHEN (0.35 g, 1 mmol) was dissolved in THF (5 mL) and cooled to 0 °C for 15 minutes. At this stage $^n\text{BuLi}$ (1.4 mL, 2 mmol) was added. After stirring for 1 hour, the solvent was removed *in vacuo* resulting in a pale yellow solid. The resulting solid was recrystallized from 15 mL of hot hexane. To aid the crystallization the resulting colourless solution was placed in the freezer at -35 °C, deposited a crop of colorless crystals (0.24 g, yield 47%). ^1H NMR (400.13 MHz, 298 K, d_8 -THF): 1.33 (36H, s, $\text{C}(\text{CH}_3)_3$), 1.61 (12H, s, CH_3), 1.81-1.85 (16H, m, OCH_2CH_2 , THF), 2.15 (12H, s, CH_3), 3.65-3.68 (16H, m, OCH_2CH_2 , THF), 6.76 (4H, s, Ph). $^{13}\text{C}\{^1\text{H}\}$ NMR (100.62 MHz, 298 K, d_8 -THF): 16.61 (CH_3), 19.75 (CH_3), 25.42 (OCH_2CH_2 , THF), 30.40 ($\text{C}(\text{CH}_3)_3$), 34.04 ($\text{C}(\text{CH}_3)_3$), 67.27 (OCH_2CH_2 , THF), 118.33, 125.59, 131.32, 132.31, 133.75, 161.95 (Ph). ^7Li NMR (155.50 MHz, 298 K, d_8 -THF): δ -0.27.

Synthesis of [(*rac*)-BIPHEN] $\text{Li}_2\text{MgBu}_2(\text{THF})_3$ (2). (*rac*)-BIPHEN (0.35 g, 1 mmol) was dissolved in hexane (10 mL) and cooled to 0 °C for 15 minutes. At this stage $^n\text{BuLi}$ (1.4 mL, 2 mmol) was added and stirred for 1 hour. $(^n\text{Bu})_2\text{Mg}$ (1 mL of a 1M solution in heptane, 1 mmol) was added at this point, and the resulting suspension was heated gently, affording a clear solution. Addition of THF (0.24 mL, 3 mmol) and slow cooling to -28 °C resulted in the formation of clear colorless crystals (0.46 g, yield 65%). ^1H NMR (400.13 MHz, 298 K, d_8 -THF): -1.73- -1.16 (2H, m, MgCH_2), -0.90 - -0.83 (2H, m, MgCH_2), 0.75-0.80 (6H, m, Bu), 1.11-1.39 (8H, s, Bu), 1.42 (18H, s, $\text{C}(\text{CH}_3)_3$), 1.51 (6H, s, CH_3), 1.77-1.79 (12H, m, OCH_2CH_2 , THF), 2.08 (6H, s, CH_3), 3.60-3.63 (12H, m, OCH_2CH_2 , THF), 6.80 (4H, s, Ph). $^{13}\text{C}\{^1\text{H}\}$ NMR (100.62 MHz, 298 K, d_8 -THF): 9.01 (MgCH_2), 15.10 (CH_3), 18.06 (CH_3), 21.43 (CH_3), 27.27 (2 x CH_2), 32.27 ($\text{C}(\text{CH}_3)_3$), 34.09 (OCH_2CH_2 , THF), 36.20 ($\text{C}(\text{CH}_3)_3$), 69.15 (OCH_2CH_2 , THF), 122.26, 127.09, 134.34, 134.64, 136.26, 161.97 (Ph). ^7Li NMR (155.50 MHz, 298 K, d_8 -THF): δ 1.41.

Synthesis of [(*rac*)-BIPHEN] $\text{Li}_2\text{Mg}(\text{CH}_2\text{SiMe}_3)_2(\text{THF})_3$ (3). (*rac*)-BIPHEN (0.35 g, 1 mmol) was dissolved in hexane (10 mL) and cooled to 0 °C for 15 minutes. At this stage $^n\text{BuLi}$ (1.4 mL, 2 mmol) was added and stirred for 1 hour. $(\text{CH}_2\text{SiMe}_3)_2\text{Mg}$ (0.2 g, 1 mmol) was added at this point, and the resulting suspension was heated gently, affording a clear solution. Addition of THF (0.24 mL, 3 mmol) and slow cooling resulted in the formation of clear colorless crystals (0.64 g, yield 82%). ^1H NMR (400.13 MHz, 298 K, *cyc*- C_6D_{12}): -2.31 (2H, m, $\text{MgCH}_2\text{Si}(\text{CH}_3)_3$), -1.65 (2H, m, $\text{MgCH}_2\text{Si}(\text{CH}_3)_3$), -0.02 (18H, s, $\text{Si}(\text{CH}_3)_3$), 1.45 (18H, s, $\text{C}(\text{CH}_3)_3$), 1.61 (6H, s, CH_3), 1.72-1.76 (12H, m, OCH_2CH_2 , THF), 2.14 (6H, s, CH_3), 3.50-3.54 (12H, m, OCH_2CH_2 , THF), 6.92 (2H, s, Ph). $^{13}\text{C}\{^1\text{H}\}$ NMR (100.62 MHz, 298 K, *cyc*- C_6D_{12}): -9.74 (SiCH_2), 3.04 ($\text{Si}(\text{CH}_3)_3$), 16.04 (CH_3), 19.53 (CH_3), 25.16 (OCH_2CH_2 , THF), 30.39 ($\text{C}(\text{CH}_3)_3$), 34.39 ($\text{C}(\text{CH}_3)_3$), 67.63 (OCH_2CH_2 , THF), 121.42, 126.07, 131.32, 132.29, 135.33, 158.97 (Ph). ^7Li NMR (155.50 MHz, 298 K, *cyc*- C_6D_{12}): δ -0.18.

Synthesis of [(*rac*)-BIPHEN] $\text{Li}_2\text{Mg}(^{neo}\text{Pe})_2(\text{THF})_2$ (4). (*rac*)-BIPHEN (0.35 g, 1 mmol) was dissolved in hexane (10 mL) and cooled to 0 °C for 15 minutes. At this stage $^n\text{BuLi}$ (1.4 mL, 2 mmol) were added and stirred for 1 hour. $(^{neo}\text{Pe})_2\text{Mg}$ (0.16 g, 1 mmol) was added at this point, and the resulting suspension was heated gently, affording a clear solution. Addition of THF (0.16 mL, 2 mmol) and slow cooling resulted in the formation of clear colorless crystals (0.25 g, yield 36%). ^1H NMR (400.13 MHz, 298 K, *cyc*- C_6D_{12}): -1.10 (2H, d, $^3J_{\text{HH}} = 15\text{Hz}$, MgCH_2), -0.13 (2H, d, $^3J_{\text{HH}} = 15\text{Hz}$, MgCH_2), 1.03 (18H, s, $\text{C}(\text{CH}_3)_3$), 1.44 (18H, s, $\text{C}(\text{CH}_3)_3$), 1.61 (6H, s, CH_3), 1.73-1.76 (12H,

m, OCH₂CH₂, THF), 2.13 (6H, s, CH₃), 3.50-3.54 (12H, m, OCH₂CH₂, THF), 6.91 (4H, s, Ph). ¹³C{¹H} NMR (100.62 MHz, 298 K, cyc-C₆D₁₂): 16.12 (CH₃), 19.53 (CH₃), 25.17 (OCH₂CH₂, THF), 25.51 (2 x MgCH₂), 30.14(C(CH₃)₃), 32.34 (C(CH₃)₃), 34.49 (C(CH₃)₃), 67.53 (OCH₂CH₂, THF), 121.01, 126.18, 130.97, 132.43, 135.55, 159.34 (Ph). ⁷Li NMR (155.50 MHz, 298 K, cyc-C₆D₁₂): δ 0.07.

Synthesis of [(rac)-BIPHEN]Li₂Mg(2-pyridine)₂(THF)₂ (5). (rac)- BIPHEN (0.35 g, 1 mmol) was dissolved in hexane (10 mL) and cooled to 0 °C for 15 minutes. At this stage ⁿBuLi (1.4 mL, 2 mmol) was added and stirred for 1 hour. (ⁿBu)₂Mg (1 mL of a 1M solution in heptane, 1 mmol) was added at this point. The solution was cooled to -60 °C, and then 2-bromopyridine (0.095 mL, 1 mmol) was added, and the resulting suspension was allowed to reach ambient temperature slowly. Addition of THF (0.16 mL, 2 mmol), gently heating and slow cooling resulted in the formation of clear colorless crystals (0.32 g, yield 47%; 94% based on 2-bromopyridine). An alternative stoichiometric synthesis could be achieved by reacting isolated crystals of [(rac)-BIPHEN]Li₂Mg(CH₂SiMe₃)₂(THF)₃ (3) (0.78 g, 1 mmol) with 2-bromopyridine (0.19 mL, 2 mmol) at -60 °C. After reaching ambient temperature, THF (0.16 mL, 2 mmol) was added, obtaining a white suspension that transforms into a deep orange solution after vigorous heating. To aid crystallization, the resulting solution was placed in the freezer at -35 °C, and deposited a crop of yellow crystals (0.46 g, yield 66%). ¹H NMR (400.13 MHz, 298 K, d₈-THF): 1.26 (18H, s, C(CH₃)₃), 1.76 (6H, s, CH₃), 1.79-1.82 (8H, m, OCH₂CH₂, THF), 2.16 (6H, s, CH₃), 3.63-3.67 (8H, m, OCH₂CH₂, THF), 6.69-6.73 (2H, m, Ar), 6.79 (2H, s, Ph), 7.06-7.10 (2H, m, Ar), 7.57 (2H, d, ³J_{HH} = 7.6 Hz, Ar), 8.24 (2H, d, ³J_{HH} = 5.2 Hz, Ar). ¹³C{¹H} NMR (100.62 MHz, 298 K, d₈-THF): 16.02 (CH₃), 19.24 (CH₃), 25.00 (OCH₂CH₂, THF), 30.33 (C(CH₃)₃), 33.88 (C(CH₃)₃), 66.86 (OCH₂CH₂, THF), 117.06 (Ar), 120.49, 125.52, 128.45 (Ph), 131.79 (Ar), 132.05, 134.50 (Ph), 135.23, 145.99 (Ar), 159.57 (Ph), 214.7 (Ar). ⁷Li NMR (155.50 MHz, 298 K, d₈-THF): δ 0.65.

Table S1: Key crystallographic and refinement parameters for compounds 1-5

	1	2	3	4	5
Empirical formula	C₆₈H₁₀₄Li₄O₉	C₄₄H₇₄Li₂MgO₅	C₄₄H₇₈Li₂MgO₅Si₂	C₄₂H₇₀Li₂MgO₄	C₄₂H₅₆Li₂MgN₂O₄
M_r	1093.27	721.22	781.43	677.17	691.08
Cryst syst	Monoclinic	Triclinic	Triclinic	Monoclinic	Monoclinic
Space group	C 2/c	P -1	P -1	C 2/ c	C 2/ c
a (Å)	15.9337(4)	11.3150(5)	11.1354(3)	11.7525(4)	16.4177(14)
b (Å)	21.4472(6)	11.6395(5)	12.7861(3)	17.2189(5)	12.3325(8)
c (Å)	18.7634(4)	18.4418(8)	17.7097(6)	21.5342(7)	20.0058(15)
α (deg)		88.063(3)	91.832(2)		
β (deg)	91.798(2)	81.313(4)	98.917(3)	100.468(3)	103.285(8)
γ (deg)		69.075(4)	105.629(2)		
V (Å³)	6408.9(3)	2242.06(17)	2391.69(12)	4285.2(2)	3942.2(5)
Z	4	2	2	4	4
μ (mm⁻¹)	0.072	0.637	0.126	0.077	0.087
T (K)	123	123	123	123	123
Reflections collected	21498	22999	20870	13998	10804
Reflections unique	7361	8791	8851	4936	4441
Reflections observed	5316	6636	6106	3735	3200
R_{int}	0.0333	0.0252	0.0311	0.0288	0.0385
No. Parameters	413	504	540	275	236
(GOF)	1.018	1.054	1.034	1.029	1.032
Final R indices	R1 = 0.0526	R1 = 0.0640,	R1 = 0.0786	R1 = 0.0491	R1 = 0.0606
[F²-2σ(F)]					
R indices (all data)	wR2 = 0.1292	wR2 = 0.1883	wR2 = 0.2336	wR2 = 0.1228	wR2 = 0.1679
Largest diff. peak and hole (e Å⁻³)	0.294 and -0.218	0.504 and -0.301	1.382 and -0.963	0.268 and -0.201	0.578 and -0.271

Figure S1. ^1H NMR of $[(rac)\text{-BIPHEN}]_2\text{Li}_4(\text{THF})_4 \cdot (\text{THF})$ (1) in $d_8\text{-THF}$




Figure S2. ^7Li NMR of $[(rac)\text{-BIPHEN}]_2\text{Li}_4(\text{THF})_4 \cdot (\text{THF})$ (1) in $d_8\text{-THF}$




Figure S2b. ^7Li NMR of $[(rac)\text{-BIPHEN}]_2\text{Li}_4(\text{THF})_4 \cdot (\text{THF})$ (1) in $cyc\text{-C}_6\text{D}_{12}$




Figure S3. ^{13}C NMR of $[(rac)\text{-BIPHEN}]_2\text{Li}_4(\text{THF})_4 \cdot (\text{THF})$ (1) in $\text{d}_8\text{-THF}$




Figure S4. ^1H NMR of $[(rac)\text{-BIPHENate}]\text{Li}_2\text{Mg}(\text{}^i\text{Bu})_2(\text{THF})_3$ (**2**) in $\text{d}_8\text{-THF}$. The resonance at approximately -0.5 ppm is an uncharacterized soluble alkyl-containing impurity that appears to be present in the commercially sourced $\text{}^i\text{Bu}_2\text{Mg}$. Note that the commercial reagent contains a significant quantity of Et_3Al .




Figure S5. ^7Li NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\textit{n}\text{Bu})_2(\text{THF})_3$ (**2**) in $\text{d}_8\text{-THF}$




Figure S6. ^{13}C NMR of [(*rac*)-BIPHEN]Li₂Mg(^{*n*}Bu)₂(THF)₃ (2) in d₈-THF




Figure S7. ^1H NMR of $[(rac)\text{-BIPHEN}]_2\text{Li}_2\text{Mg}(\text{THF})_4$ (2b) in *cyc*- C_6D_{12}




Figure S8. ^1H NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{CH}_2\text{SiMe}_3)_2(\text{THF})_3$ (**3**) in *cyc*- C_6D_{12}




Figure S9. ^7Li NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{CH}_2\text{SiMe}_3)_2(\text{THF})_3$ (3) in $\text{cyc-C}_6\text{D}_{12}$




Figure S10. ^{13}C NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{CH}_2\text{SiMe}_3)_2(\text{THF})_3$ (3) in $\text{cyc-C}_6\text{D}_{12}$




Figure S11. ^1H NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{neoPe})_2(\text{THF})_2$ (4) in $\text{cyc-C}_6\text{D}_{12}$




Figure S12. ^7Li NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{neoPe})_2(\text{THF})_2$ (4) in $\text{cyc-C}_6\text{D}_{12}$




Figure S13. ^{13}C NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{neo-Pe})_2(\text{THF})_2$ (4) in $\text{cyc-C}_6\text{D}_{12}$




Figure S14. ^1H NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(2\text{-pyridyl})_2(\text{THF})_2$ (5) in $\text{d}_8\text{-THF}$




Figure S15. ^7Li NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(2\text{-pyridyl})_2(\text{THF})_2$ (5) in $\text{d}_8\text{-THF}$





Figure S16. ^{13}C NMR of $[(rac)\text{-BIPHEN}]\text{Li}_2\text{Mg}(\text{2-pyridyl})_2(\text{THF})_2$ (5) in $\text{d}_8\text{-THF}$



Solution studies of starting materials.

Figure S17. ^1H NMR of a *in situ* mixture (*rac*)-BIPHEN- $\text{H}_2 + 2 \text{ }^n\text{BuLi} + \text{ }^n\text{BuMgCl}$ in $\text{d}_8\text{-THF}$




Figure S18. ^7Li NMR of a *in situ* mixture (*rac*)-BIPHEN- $\text{H}_2 + 2 \text{ }^n\text{BuLi} + \text{ }^n\text{BuMgCl}$ in $\text{d}_8\text{-THF}$




Figure S19. ^1H NMR of a *in situ* mixture (*rac*)-BIPHEN- $\text{H}_2 + 2 \text{ }^n\text{BuLi} + \text{ }^n\text{BuMgCl} + \text{ }^n\text{BuLi}$ in $\text{d}_8\text{-THF}$




Figure S20. ^7Li NMR of a *in situ* mixture (*rac*)-BIPHEN- $\text{H}_2 + 2$ $^n\text{BuLi} + ^n\text{BuMgCl} + ^n\text{BuLi}$ in d_8 -THF




Figure S21. ^1H NMR of a *in situ* mixture (rac)-BIPHEN- $\text{H}_2 + 2$ $^n\text{BuLi} + (^n\text{Bu})_2\text{Mg}$ in $\text{d}_8\text{-THF}$




Figure S22. ^7Li NMR of a *in situ* mixture (rac)-BIPHEN- $\text{H}_2 + 2$ $^n\text{BuLi} + (^n\text{Bu})_2\text{Mg}$ in $\text{d}_8\text{-THF}$




Figure S23. ^1H NMR comparison of Routes A & B in $\text{d}_8\text{-THF}$




Figure S24. ^1H NMR of a mixture BIPHEN + 2BuLi + MgBu₂ after reflux.




Figure S25. ^7Li NMR of a mixture BIPHEN + 2BuLi + MgBu₂ after reflux.






Figure S26. ^1H NMR of a mixture BIPHEN + 2BuLi + MgBu₂ after reflux. t = 2 days.




^1H NMR spectrum of $[(rac)\text{-BIPHEN}]_2\text{Li}_4(\text{THF})_4 \cdot (\text{THF})$ (1), TPhN, PhN and TMS at 25 °C in $\text{cyc-C}_6\text{D}_{12}$ (traces of grease are also observed).



^1H -DOSY NMR spectrum of 1 and the standards TPhN, PhN and TMS in $\text{cyc-C}_6\text{D}_{12}$ at 298 K (some traces of grease are also observed).



$\log D - \log \text{FW}$ representation from the ^1H -DOSY data obtained for the mixture of 1, TPhN, PhN and TMS in $\text{cyc-C}_6\text{D}_{12}$



Possible species of [(*rac*)-BIPHEN]₂Li₄(THF)₄ · (THF) (1) in *cyc*-C₆D₁₂ with errors (in brackets) respect to the FW value predicted through the DOSY study.

FW predicted for [(*rac*)-BIPHEN]₂Li₄(THF)₄ · (THF) (1) in *cyc*-C₆D₁₂ = 667.4 gmol⁻¹

- A [(*rac*)-BIPHEN]₂Li₄(THF)₄ C₆₄H₉₆Li₄O₈ = 1020.77 gmol⁻¹ (36%)
- B [(*rac*)-BIPHEN]₂Li₄ C₄₈H₆₄Li₄O₄ = 732.5 gmol⁻¹ (9%)
- C [(*rac*)-BIPHEN]Li₂ C₂₄H₃₂Li₂O₂ = 366.4 gmol⁻¹ (-82%)
- D [(*rac*)-BIPHEN]Li₂(THF)₄ = 654.86 gmol⁻¹ (-1.9%)

¹H-DOSY NMR spectrum of 2 in *cyc*-C₆D₁₂ at 298 K.

